[Preliminary and clinical investigations of cefmetazole in the obstetric and gynecological field].
1. The serum concentration of cefmetazole (CMZ) was 56.8 +/- 13.3 micrograms/ml at 1 hour after one-shot intravenous injection of 2 g. Half-life was 1.1 hours, indicating that the drug is adsorbed rapidly. In addition, CMZ was detected at high concentrations in the endometrium, myometrium, ovary, uterine tube and cervix uteri. The concentration was especially high in the uterine tube and ovary. It was also demonstrated in the fetus and fetal membrane, though at low concentration. 2. Clinically one-shot intravenous injection of 1 to 2 g of CMZ were given 2 times daily to 15 patients with intrauterine infection, adnexitis, intrapelvic infection or postoperative wound infection. The drug was evaluated to be effective in 15 or 80% of them. No special side effects were found.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy; D015311:Cefmetazole; D002511:Cephalosporins / Q000378:metabolism*; D002513:Cephamycins / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy; D005836:Genitalia, Female / Q000378:metabolism*; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D014018:Tissue Distribution
D002511:Cephalosporins; D002513:Cephamycins; D015311:Cefmetazole